HYPR
Hyperfine, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.81
−2.83%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 16.5M | 13.6M | 12.9M | 11.0M | 6.8M |
| Cost of Revenue | 8.0M | 6.8M | 7.0M | 6.3M | 5.9M |
| Gross Profit | 8.5M | 6.8M | 5.9M | 4.8M | 907.0K |
| Operating Expenses | |||||
| R&D Expense | 15.6M | 17.5M | 22.5M | 22.5M | 28.2M |
| SG&A Expense | 26.5M | 26.4M | 26.6M | 30.4M | 46.6M |
| General & Admin Expense | 16.2M | 16.3M | 17.5M | 20.3M | 32.4M |
| Selling & Marketing Expense | 10.3M | 10.1M | 9.1M | 10.1M | 14.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 42.1M | 43.8M | 49.1M | 52.9M | 74.8M |
| Cost and Expenses | 50.2M | 50.6M | 56.1M | 59.1M | 80.7M |
| Operating Income (EBIT) | (33.6M) | (37.1M) | (43.2M) | (48.1M) | (73.9M) |
| Non-Operating | |||||
| Interest Income | 993.0K | 1.0M | 2.5M | 3.8M | 761.0K |
| Interest Expense | 616.0K | — | — | — | — |
| Net Interest Income | 377.0K | 1.0M | 2.5M | 3.8M | 761.0K |
| Other Non-Op Income/Expense | (1.2M) | 1.5M | 2.5M | 3.9M | 710.0K |
| Non-Operating Income (excl Interest) | 621.0K | (1.5M) | (2.5M) | (3.9M) | (710.0K) |
| EBT (Pre-Tax Income) | (34.9M) | (35.6M) | (40.7M) | (44.2M) | (73.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (34.9M) | (35.6M) | (40.7M) | (44.2M) | (73.2M) |
| Earnings from Cont. Ops | (34.9M) | (35.6M) | (40.7M) | (44.2M) | (73.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (34.9M) | (35.6M) | (40.7M) | (44.2M) | (73.2M) |
| Per Share | |||||
| Basic EPS | ($0.38) | ($0.43) | ($0.56) | ($0.62) | ($1.04) |
| Diluted EPS | ($0.38) | ($0.43) | ($0.56) | ($0.62) | ($1.04) |
| Revenue Per Share | $0.17 | $0.14 | $0.18 | $0.15 | $0.10 |
| Shares | |||||
| Basic Shares Outstanding | 99.8M | 94.2M | 72.4M | 71.3M | 70.4M |
| Diluted Shares Outstanding | 99.8M | 94.2M | 72.4M | 71.3M | 70.4M |
| Profitability Metrics | |||||
| EBITDA | (32.4M) | (33.4M) | (39.7M) | (43.2M) | (72.1M) |
| D&A | 1.8M | 2.2M | 1.0M | 1.1M | 1.0M |
| EBIT | (34.2M) | (35.6M) | (40.7M) | (44.2M) | (73.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026